Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
The Philippines Tuberculosis Diagnostics market was valued at USD 433.09 Million in 2025 and is expected to grow at a CAGR of 5.10%, reaching USD 712.21 Million by 2035. The market growth is driven by the development of next-generation molecular diagnostic assays, integration of automated sample preparation and multiplex PCR technologies, expansion of decentralized testing networks, deployment of portable point-of-care diagnostic platforms, improved access to rapid drug-resistance testing, and public–private partnerships.
Compound Annual Growth Rate
5.1%
Value in USD Million
2026-2035
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Tuberculosis diagnostics refers to the range of medical tests, laboratory techniques, and diagnostic technologies used to detect Mycobacterium tuberculosis (M. tuberculosis), the bacterium responsible for tuberculosis. The market was valued at USD 433.09 Million in 2025, driven by the high burden of tuberculosis, increasing incidence of drug-resistant TB, government-led TB elimination initiatives, rising investments in public healthcare infrastructure, growing adoption of rapid molecular diagnostic technologies, expanding access to point-of-care testing, increased screening among high-risk populations, and rising demand for early diagnosis, accurate detection, and drug-resistance profiling.
|
Analysis Type |
Factors |
Example |
|
Market Drivers |
Government-led screening expansion |
WHO and the Philippine DOH planned to screen 12 million Filipinos by 2026, alongside a proposed PHP 4.2 billion TB-services budget. |
|
Market Restraints |
Limited laboratory resources and supply-chain disruptions |
RITM reported delays in TB culture and drug-susceptibility testing in January 2026, while WHO identified diagnostic disruptions following USAID funding cuts. |
|
Market Opportunities |
Government-funded molecular testing expansion |
In September 2025, the Philippine Health Technology Assessment Division reported government financing approval for cartridge-based and chip-based RT-PCR tests for tuberculosis. |
The following section outlines the key factors influencing the growth of the market, including major drivers, restraints, and emerging opportunities.
Government-Led Screening Expansion and Adoption of Molecular Testing is Likely to Enhance the Market Value
The expansion of government-led tuberculosis screening and adoption of advanced diagnostic technologies are supporting market growth in the Philippines. On November 12, 2025, WHO and the Department of Health (DOH) announced plans to screen 12 million Filipinos by 2026, alongside a proposed increase in the 2026 TB-services budget to PHP 4.2 billion. Separately, on May 6, 2026, WHO and the Stop TB Partnership published a toolkit supporting decentralized molecular TB testing through near point-of-care nucleic acid amplification tests and tongue-swab testing. These initiatives can strengthen diagnostic accessibility and increase demand for TB testing technologies.
Procurement Delays and Diagnostic Supply-Chain Disruptions to Constrain the Market Growth
Public-sector resource limitations and disruptions in diagnostic supply chains constrain the expansion of tuberculosis diagnostic services in the Philippines. In January 2026, the Research Institute for Tropical Medicine (RITM) reported delays in TB culture and drug-susceptibility testing due to limited resources. Similarly, WHO's 2025 assessment highlighted disruptions at partner-supported diagnostic sites following USAID funding cuts. These challenges reduce effective laboratory throughput, weaken instrument utilization and increase operating uncertainty, discouraging sustained investment in molecular testing capacity.
Expansion of Government-Funded Molecular Testing and Decentralized Diagnostics to Boost the Market Demand
The expansion of affordable molecular testing and decentralized diagnostic services presents an opportunity to improve tuberculosis (TB) detection across the Philippines, particularly in underserved areas. In September 2025, the Philippine Health Technology Assessment Division reported government approval of financing for cartridge-based and chip-based RT-PCR tests for drug-susceptible and drug-resistant TB. Such developments could support wider diagnostic access and future market demand.
The market is witnessing several key trends including the growing adoption of rapid molecular testing, expansion of decentralized tuberculosis screening, and increasing emphasis on early detection and drug-resistance diagnosis.
Shift Toward Rapid Molecular Testing and Decentralized Screening
The market is supported by continued emphasis on molecular testing for early and accurate TB detection. In December 2025, the Philippine Department of Health reiterated Xpert MTB/RIF as the primary diagnostic test for all presumptive TB cases under Department Circular DC 2024-0212. This policy reinforces the role of molecular diagnostics in national testing pathways and supports demand for diagnostic platforms and related consumables across the country's healthcare system.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The market is segmented by disease type into pulmonary tuberculosis diagnostics, extrapulmonary tuberculosis diagnostics, and latent tuberculosis infection diagnostics. Among these, latent tuberculosis diagnostics is expected to maintain a leading position, supported by increasing emphasis on early identification of TB infection and preventive treatment among high-risk populations. The growing focus on tuberculosis elimination programs and systematic screening is expected to strengthen demand for latent TB testing, supporting the segment's market position throughout the forecast period.
The key features of the market report include strategic initiatives by leading players. The major companies in the market are as follows:
QIAGEN develops molecular diagnostic technologies, sample preparation systems, and nucleic acid testing solutions. Its portfolio includes the QIAstat-Dx and QIAsymphony platforms, alongside assays for infectious disease detection. The company supports tuberculosis diagnosis through molecular testing and sample processing technologies, serving clinical laboratories, hospitals, and public health institutions across international markets.
Cepheid, a subsidiary of Danaher Corporation, specializes in automated molecular diagnostic systems based on its GeneXpert platform. Its tuberculosis portfolio includes Xpert MTB/RIF and Xpert MTB/RIF Ultra assays, which detect Mycobacterium tuberculosis and identify genetic markers associated with rifampicin resistance. Its technologies support rapid TB diagnosis across hospitals, laboratories, and decentralized healthcare settings.
Molbio Diagnostics is an Indian molecular diagnostics company known for its Truenat platform, a portable, chip-based real-time PCR system. Its tuberculosis portfolio includes Truenat MTB, MTB Plus, and MTB-RIF Dx assays. These technologies enable decentralized TB testing and drug-resistance detection, supporting national tuberculosis control programmes and diagnostic access in resource-limited settings.
Roche develops molecular diagnostic technologies, laboratory automation systems, and infectious disease testing solutions. Its diagnostic portfolio includes PCR-based platforms and assays used for detecting infectious pathogens. Through its molecular diagnostics capabilities, the company participates in the broader tuberculosis diagnostic ecosystem, supporting clinical laboratories and healthcare institutions with automated testing infrastructure.
Other key players in the market include Abbott, Becton, Dickinson and Company (BD), FUJIFILM Holdings Corporation, Eiken Chemical Co., Ltd., Qure.ai Technologies Private Limited, and Hain Lifescience GmbH.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Diagnostics
The market is segmented by diagnostic technology, covering conventional microscopy and culture-based methods alongside rapid molecular assays and immunological tests. Increasing adoption of nucleic acid amplification technologies, automated testing platforms, and molecular drug-resistance detection supports improvements in diagnostic accuracy, turnaround time, and access to TB testing.
Market Breakup by Disease Type
The market is categorized by disease type into pulmonary, extrapulmonary, and latent tuberculosis diagnostics. Demand is supported by the substantial burden of pulmonary TB, the need to identify infections affecting extrapulmonary sites, and expanded screening among high-risk populations. Improved molecular testing capabilities are also strengthening diagnostic approaches for different TB presentations.
Market Breakup by End User
The segment comprises hospitals, diagnostic laboratories, research laboratories, and other healthcare facilities. Hospitals contribute through patient screening, clinical diagnosis, and treatment monitoring, while diagnostic laboratories support specialized molecular testing, microscopy, culture, and drug-susceptibility analysis. Government TB programmes and expanding diagnostic networks further support institutional demand for tuberculosis testing services.
This report is developed through a structured mixed-methods research approach combining secondary research, market analysis, and data validation:
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Diagnostics |
|
| Breakup by Disease Type |
|
| Breakup by End User |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.